Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
LEO Pharma, 4SC Ink Dermatology Deal
by Rick Mullin
March 4, 2013
| A version of this story appeared in
Volume 91, Issue 9
Leo Pharma, a Danish dermatology drug specialist, has signed a research and licensing agreement with Germany’s 4SC Discovery to research, develop, and commercialize an oral treatment for inflammatory skin disease. The partners say they are working on a compound in early-stage development that could significantly reduce symptoms of psoriasis. 4SC will receive $1.3 million in R&D financing and could get up to $125 million in milestone payments plus additional royalties.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X